We held an investor presentation on February 19th to attract investment. Due to lack of preparation, we were unable to present a satisfactory IR presentation. Investor S decided to consider investing in the company through complementary investment considering the potential value of the company's Anyfusion cylinder pump and Anyfusion ACPi system.

The initial investment is 2 to 6 billion won, including Anyfusion cylinder pump and cartridge set, Anyfusion ACPi system and cartridge kit set CE and FDA certification fees, HIS integration, Bar code scanner, prescription and dispensing audit function on the monitor, installation in BSC, dispensing robot can dispense 50 to 60 cases per day, CSTD function 40 to 60 cases per hour of anti-cancer drugs and TPN,  Anyfusion ACPi system Pro, which automatically connects vials to multifunctions such as PCA balloon and syringe filling, and is automatically controlled in conjunction with electronic scales, will be used for development costs, global conferences and exhibitions, and pump and cartridge production costs, and aims to IPO within three years after investment.

In the domestic market, Anyfusion cylinder pump is a new business model market strategy that focuses on cylinder cartridges with competitive prices and competitive safety and efficacy, which can reduce the cost of medical institutions and reduce the workload of medical staff, as well as the effectiveness of infection prevention, and is conducting demonstrations and demos at major hospitals, A Hospital, S Hospital, and Y University Hospital.  Through sales support, we are creating results that immediately realize synergy as distributor V plays the role of field sales, so if we expand to local sales, we expect sales of nearly 10 billion won in the first year of investment; in the second year, we aim for sales in the mid-30 billion won range and net profit of nearly 100%, including overseas exports with CE certification of the Quick Anyfusion ACPi system; in the third year, we aim to IPO with sales of more than 50 billion won and net profit of more than 100% with FDA certification and the launch of Anyfusion ACPi Pro. Focusing on medical insurance coverage, we plan to sell Anyfusion cylinder pump based on cylinder cartridges for pumps in Korea and Anyfusion ACPi system based on ACPi kit set covered by CSTD in overseas.

Anyfusion semi ACPi system is well received by hospitals, but no hospital is willing to purchase it first.  In Korea, there are high expectations for the dispensing equipment as a reference for the dispensing robot, which has the function of quickly dispensing 40~50 chemotherapy drugs per hour with exposure to chemotherapy drugs for CSTDs and leakage prevention, and automatically filling PCA balloons with strong physical strength to facilitate laborious fluid dispensing, but resistance to manual equipment, reliability concerns for equipment that has not yet been confirmed, and burden on consumable costs that cannot be estimated are identified as factors hindering rapid adoption. Overseas, there are few references to dispensing robots that do not use CSTD, and most of them apply CSTD to syringes and do not introduce robots because they believe that manual work is more reasonable than dispensing robots with lower cost performance. Since many countries in Europe, including the United States, Japan, Spain, and Italy, as well as Saudi Arabia, Qatar, Kuwait (Middle East), Algeria (Africa), and the Maldives, continue to require CE rapid certification of the ACPi system, overseas exports are expected to grow rapidly after the certification is completed.

The first year is a strategy to maximize sales with competitively priced cylinder pumps centered on cylinder cartridges supplied with safety and effectiveness in Korea. In particular, the cartridge set for Anyfusion cylinder pumps, which is supplied based on safety and effectiveness and blocks exposure and leakage of anticancer drugs with CSTD function by applying patented MCSTD1 and syringe adapter, is a strategy to maximize sales by collaborating with V distributors who have exclusive competitiveness and sales know-how in daycare centers (day wards or injection rooms) than existing sets that cannot be calculated. The anti-cancer drug injection market is more than five times larger than the anti-cancer drug dispensing market in the daycare center (day ward, injection room), and we will maximize sales in Korea by leading the anti-cancer drug injection market centered on major A hospitals and S hospitals with an annual anti-cancer drug injection market of more than KRW 4 billion, and target the global anti-cancer drug dispensing market with an ACPi system that dispenses with a device rather than a person with a stable and efficacy-oriented salary system as a secondary investment to maximize sales and maximize the IPO effect with high net profit.

Thank you.